Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium’s Dosing Regimens in Multiple Sclerosis
November 21, 2023– Fundamental New Patent Covers Treatment of Multiple Sclerosis Into 2038 and Beyond – – Third U.S. Patent Directed to…Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 14, 2023– Positive Interim Analysis from Phase 2 CALLIPER Trial Showed Improvements in Serum Neurofilament Light Chain for Vidofludimus Calcium, Consistent…Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update
November 7, 2023– Webcast to be Held at 8:00 am ET on November 14, 2023 – NEW YORK, November 7, 2023 – Immunic,…Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts
November 2, 2023NEW YORK, November 2, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…Immunic to Participate in Scientific and Industry Conferences in November
October 26, 2023NEW YORK, October 26, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023
October 16, 2023NEW YORK, October 16, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023
October 15, 2023NEW YORK, October 15, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting
October 11, 2023– Improvement in Serum Neurofilament Light Chain (NfL) Observed in Both Treatment Arms ofVidofludimus Calcium Over Placebo – – NfL…Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
October 9, 2023– 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis…Immunic to Participate in Scientific Conferences in October
October 4, 2023NEW YORK, October 4, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…